<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00976118</url>
  </required_header>
  <id_info>
    <org_study_id>AB04024</org_study_id>
    <nct_id>NCT00976118</nct_id>
  </id_info>
  <brief_title>Activity of Masitinib (AB1010) in Mild to Moderate Alzheimer's Disease</brief_title>
  <official_title>A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Efficacy of Oral AB1010 in Adults Patients With Mild to Moderate Alzheimer-type Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AB Science</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AB Science</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase 2 study was designed to evaluate the activity of oral masitinib (AB1010)
      administered at 2 dose levels during 24 weeks to patients with mild to moderate confirmed
      Alzheimer's type disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change from baseline in ADAS-Cog</measure>
    <time_frame>week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change from baseline in CIBIC-plus</measure>
    <time_frame>week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in CDR</measure>
    <time_frame>week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in MMSE</measure>
    <time_frame>week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>oral masitinib (AB1010)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>masitinib (AB1010) 3 or 6 mg/kg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>masitinib (AB1010)</intervention_name>
    <description>oral masitinib 3 or 6 mg/kg/day</description>
    <arm_group_label>oral masitinib (AB1010)</arm_group_label>
    <other_name>AB1010</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>matching placebo to masitinib</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Outpatients from both sex

          2. Age ≥ 50 years at screening

          3. Menopause ≥ 2 years for women

          4. Dementia of Alzheimer's type, according to DSM IV criteria

          5. Probable Alzheimer' disease according to NINCDS-ADRDA criteria

          6. MMSE ≥ 12 and ≤ 26 at baseline

          7. CDR of 1 or 2 at baseline

          8. Treated for a minimum of 6 months with a stable dose of cholinesterase inhibitors
             (donepezil, rivastigmine or galantamine) at baseline, and/or a stable dose of
             memantine for a minimum of 3 months at baseline, with no changes foreseen in therapy
             throughout the study

          9. Presence of a reliable caregiver

         10. Patient, identified caregiver and, if applicable, patient surrogate are able and
             willing to comply with study visits and procedures per protocol, understand, sign, and
             date the written voluntary informed consent form at the screening visit prior to any
             protocol-specific procedures performed

         11. Affiliated to the French Social Security regimen

        Exclusion Criteria:

          1. Any cause of dementia not due to Alzheimer's disease :

               -  other central nervous conditions causing progressive deficits in memory and
                  cognition, e.g. cerebrovascular disease, Parkinson's disease, Huntington's
                  disease, brain tumor…

               -  systemic conditions known to cause dementia, e.g., hypothyroidism, untreated
                  vitamin B12 or folic acid deficiency, niacin deficiency, neurosyphilis, HIV
                  infection…

               -  substance-induced conditions

          2. Alzheimer disease with delusions or delirium

          3. Treatment with any registered or putative cognitive enhancer or disease modifier other
             than donepezil, galantamine, rivastigmine or memantine

          4. Uncontrolled depression at screening

          5. Evidence of psychosis and/or use of antipsychotic drugs at screening, or history of
             significant psychotic disorder or hospitalization for psychiatric disorders

          6. Active current bacterial, viral (including hepatitis B and C, HIV, EBV, CMV, herpes
             zoster, herpes simplex), fungal, mycobacterium, protozoan, or other infection.

          7. History of infection requiring hospitalization or treatment with antibiotics within 2
             weeks of screening

          8. Inadequate organ function, defined as follows : total bilirubin ≥ 1.5 x ULN, SGOT and
             SGPT ≥ 2.5 x UNL, creatinine clearance calculated by Crocroft method &lt; 35 ml/mn, ANC ≤
             2500, platelets ≤ 100 000 at baseline

          9. Treatment with any investigational agent within 4 weeks of screening,

         10. Men and their partner refusing to use 2 methods of medically acceptable forms of
             contraception during the study.

         11. History of poor compliance or history of drug/alcohol abuse, or excessive alcohol
             beverage consumption that would interfere with the ability to comply with the study
             protocol, or current or past psychiatric disease that might interfere with the ability
             to comply with the study protocol or give informed consent

         12. Any condition that, in the investigator's opinion, could be detrimental to subjects
             participating in this study as life expectancy &lt; 1 year, or any clinically important
             deviations from normal clinical laboratory values or concurrent medical events.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226277/</url>
    <description>Publication of results</description>
  </link>
  <results_reference>
    <citation>Piette F, Belmin J, Vincent H, Schmidt N, Pariel S, Verny M, Marquis C, Mely J, Hugonot-Diener L, Kinet JP, Dubreuil P, Moussy A, Hermine O. Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial. Alzheimers Res Ther. 2011 Apr 19;3(2):16. doi: 10.1186/alzrt75.</citation>
    <PMID>21504563</PMID>
  </results_reference>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>September 11, 2009</study_first_submitted>
  <study_first_submitted_qc>September 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2009</study_first_posted>
  <last_update_submitted>December 12, 2018</last_update_submitted>
  <last_update_submitted_qc>December 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dementia of Alzheimer's type</keyword>
  <keyword>mild to moderate Alzheimer's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

